Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S announced updates to its Articles of Association, including ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Shares of Genmab A/S Sponsored ADR (GMAB) have gained 3.8% over the past four weeks to close the last trading session at ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS. Read why I remain bullish on GMAB stock.

Genmab A/S (NASDAQ:GMAB) develops antibody therapeutics for the treatment of cancer and other diseases. H.C. Wainwright analyst Ram Selvaraju reiterated a “Buy” rating on the company’s ...

GMAB stands above RGEN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that GMAB is the superior value option right now. Zacks Names #1 Semiconductor Stock ...

GMAB currently has a forward P/E ratio of 22.98, while TECH has a forward P/E of 34.77. We also note that GMAB has a PEG ratio of 0.93. This popular metric is similar to the widely-known P/E ratio ...